Roche remains confident in the prospects for its soon-to-be-filed oral BTK drug fenebrutinib for multiple sclerosis, despite safety concerns.
FDA approves Regeneron’s hearing loss gene therapy Otarmeni
Regeneron has won the first ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans


